Ligand Pharmaceuticals is trading 4.01% down at $294.46, with sector weakness the most plausible explanation, though no direct causal link was established.
- On October 6, 2026, the XBI ETF was down about 2.5% during the session, offering biotech-sector context.
- No clear company-specific announcement explaining the decline surfaced in available search results. The broader market was higher, so general market sentiment is not a strong explanation.